Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genor Biopharma Holdings Limited ( (HK:6998) ) just unveiled an update.
Genor Biopharma Holdings Limited announced advancements in the clinical evaluation of their drug candidate, GB261, a bispecific antibody targeting CD20 on B-cells and CD3 on T-cells. The drug, licensed to Candid Therapeutics, Inc., has shown promise in treating autoimmune diseases with initial patients tolerating the treatment well. This development could enhance Genor Biopharma’s positioning in the biotechnology industry, potentially impacting stakeholders positively if successful.
More about Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited is a biotechnology company incorporated in the Cayman Islands, focusing on developing innovative therapies. Their primary products include bispecific antibodies, with a market focus on treating autoimmune and inflammatory diseases.
YTD Price Performance: 40.46%
Average Trading Volume: 1,012,876
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.27B
See more data about 6998 stock on TipRanks’ Stock Analysis page.